Women Who Used Both Hormone Treatments Had Healthier Brain Vessels
A woman’s hormone history, from birth control pills in her younger years to hormone therapy around menopause, may still be visible in her brain at age 70. Scans of 352 Swedish women found that those who had used both treatments had lower odds of marked small vessel brain damage, meaning wear and tear in the brain’s tiniest blood vessels, than women who had used neither. Their white matter, the nerve fibers that carry signals between brain regions, also looked healthiest of any group measured.
Women make up two-thirds of dementia cases worldwide, and researchers suspect estrogen, which rises and falls sharply over a woman’s life, may play a part. Estrogen has been tied to protective effects on blood vessels and brain tissue, but how a lifetime of swings shapes an aging brain has stayed unclear.
Published in the journal Neurology, the work did not measure estrogen directly. Instead, researchers used each woman’s reproductive timeline and her history of birth control pills and menopausal hormone therapy as stand-ins for exposure. According to the authors, no earlier study had examined the two treatments together against late-life brain scans.
Brain Scans of 352 Swedish Women Tie Hormone Use to Healthier Vessels
Participants came from the Gothenburg H70-1944 Birth Cohort, a long-running study of people born in 1944 in Gothenburg, Sweden. Trained staff interviewed each woman about when her periods started and stopped and whether she had ever used birth control pills or menopausal hormone therapy. About 73% reported pill use, and 61% reported hormone therapy. The years between first period and menopause, called the reproductive span, averaged about 37 years.
Women in the study were about 70, free of dementia, and scored well on memory tests. Nearly 70% had high blood pressure. About one in three carried APOE-e4, a gene variant that raises Alzheimer’s risk.
MRI scans were taken at 70 and again five years later, when 286 women returned and 205 had usable scans. Radiologists scored small vessel disease from 0 to 4, giving one point each for brain scarring, tiny bleeds, small patches of dead tissue, and enlarged spaces around vessels. About 41% of the women showed at least one sign, and two or more counted as marked disease. A second technique, which tracks how water moves along nerve fibers, gauged white matter health.
A longer reproductive span tended to go with less small vessel damage, driven more by a later menopause than an early first period. That link weakened once researchers adjusted for the many comparisons run in the study, a safeguard against chance findings.
Hormone therapy around menopause showed firmer results. Users had about 60% lower odds of marked small vessel disease, plus healthier white matter, and both results survived that safeguard. Individual signs, including microbleeds and enlarged spaces around vessels, were also less common among users, but those links did not hold up. Birth control use, analyzed separately, was linked to better white matter, though that finding faded too.
Birth Control Plus Menopause Hormone Therapy Linked to Lower Odds of Vessel Damage
Women who used both treatments showed the clearest pattern. In the white matter analysis, 157 had used both and 46 had used neither. The small vessel finding amounts to roughly 70% lower odds, though it rested on only 14 marked cases among those who used both. That finding and the white matter result both held up under the safeguard. Women who used only one treatment showed no clear differences in this head-to-head comparison, though those groups were small.
Pills and hormone therapy did not multiply each other’s effects, which fits benefits adding up. The authors floated one possibility: early pill use may start protecting white matter, and later hormone therapy may sustain it. That idea remains untested.
Alzheimer’s Signals Stayed Weak and Five-Year Changes Showed No Clear Gap
Hormone use showed no overall link to thinning in brain regions that shrink early in Alzheimer’s disease, or to spinal fluid markers of early Alzheimer’s. One exception appeared: hormone therapy was tied to thicker tissue there, but only among APOE-e4 carriers, and the result did not survive the safeguard, so the authors urged caution.
Over five years, brain changes built up at similar rates in hormone users and nonusers. Hormone therapy users did show a trend toward slower white matter scarring, though chance could explain it. In short, the results point toward blood vessels rather than a direct effect on Alzheimer’s disease.
Observational data cannot show that hormones prevent dementia or cause healthier vessels, and no one should start or stop a medication without talking to a doctor. Still, a woman’s hormonal timeline, from her first period through pill use in her reproductive years to hormone therapy near menopause, may be linked to the health of her brain’s blood vessels decades later. Reproductive history is worth recording whenever scientists study brain aging in women.
